{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:19:10Z","timestamp":1783351150653,"version":"3.54.6"},"reference-count":62,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Metastatic prostate cancer (PC) incidence has increased in US men, partly due to changes in prostate-specific antigen (PSA) screening recommendations. However, few studies have examined contemporary PSA screening practices in large US health care systems.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To describe and examine contemporary PSA testing practices associated with metastatic PC incidence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study included veterans within the Veterans Health Administration that received a prostate needle biopsy (PNB) between January 2015 and December 2023 with follow-up through 2024, excluding those with a history of PC. Data were analyzed between July 1, 2023, and November 6, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n PSA tests were retrieved from the VA Corporate Data Warehouse and categorized by age at first VA PSA (&amp;lt;50, 50-59, and \u226560 years) and by longest interval between consecutive VA PSA tests in the 5 years before PNB (\u226424 vs &amp;gt;24 months). Clinical, laboratory, pathological, demographic, and census block group-level socioeconomic status data were obtained from the VA Multi-OMICS Analysis Platform for Prostate Cancer database.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Multivariable Cox models estimated hazard ratios (HRs) from time of first VA PSA to first PNB, evaluated risk of metastatic (regional or distant) vs localized PC or benign diagnosis, and adjusted for sociodemographic and clinical covariates.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 103\u202f067 participants of whom 20\u202f233 (19.6%) were younger than 50 years at first PSA, 31\u202f546 (30.6%) were non-Hispanic Black, 58\u202f264 (56.5%) were non-Hispanic White, and 13\u202f277 (12.9%) had other race or ethnicity. Of all participants, 22\u202f190 (21.5%) had a first PSA value of 1 ng\/mL or less, 52\u202f939 (51.4%) had a screening interval of 24 months or less, and 3773 (3.7%) were diagnosed with metastatic PC at time of PNB. Compared with men aged younger than 50 years at first PSA, those aged 50 to 59 years (adjusted HR [aHR], 1.27; 95% CI, 1.24-1.29) and 60 years or older (aHR, 2.37; 95% CI, 2.33-2.42) had higher risk of metastatic PC. Men with longer screening intervals had higher risk of metastatic PC (aHR, 1.14; 95% CI, 1.13-1.16). Men aged younger than 50 years with shorter screening intervals had lower rates of metastatic PC (adjusted risk ratio, 0.10; 95% CI, 0.09-0.12) compared with men aged 60 years or older with longer screening intervals.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, few veterans had the most favorable combinations of screening factors in relation to metastatic PC, suggesting potential for further screening optimization.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.21741","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:03:41Z","timestamp":1783350221000},"page":"e2621741","source":"Crossref","is-referenced-by-count":0,"title":["Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans"],"prefix":"10.1001","volume":"9","author":[{"given":"Mehrnaz","family":"Siavoshi","sequence":"first","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Department of Urology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Frochen","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Department of Urology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Fakunle","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananta","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"University of Rochester, School of Medicine and Dentistry, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley-Marie Y.","family":"Green-Lott","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Department of Urology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa V.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Department of Urology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Kwan","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Department of Urology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace","family":"Haroldsen","sequence":"additional","affiliation":[{"name":"Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah"},{"name":"University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atim","family":"Effiong","sequence":"additional","affiliation":[{"name":"Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, Utah"},{"name":"University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent S.","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Rebbeck","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Veterans Affairs Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari S.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Section of Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla P.","family":"Garraway","sequence":"additional","affiliation":[{"name":"Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"Department of Urology, University of California, Los Angeles"},{"name":"Jonsson Comprehensive Cancer Center, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"2","key":"zoi260606r1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.","volume":"104","author":"Andriole","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi260606r2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer.","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"zoi260606r3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/jnci\/djz127","article-title":"Overdiagnosis and lives saved by reflex testing men with intermediate prostate-specific antigen levels.","volume":"112","author":"Gulati","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"zoi260606r4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/1055-9965.EPI-16-0434","article-title":"Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms.","volume":"26","author":"Gulati","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"17","key":"zoi260606r5","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European Study of Prostate Cancer Screening \u201423-year follow-up.","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi260606r6","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force.","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"issue":"18","key":"zoi260606r7","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for Prostate Cancer: US Preventive Services Task Force recommendation statement.","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"zoi260606r8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/jnci\/djac066","article-title":"Grade migration of prostate cancer in the United States during the last decade.","volume":"114","author":"Borregales","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"zoi260606r9","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4111\/icu.2017.58.6.423","article-title":"US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.","volume":"58","author":"Gejerman","year":"2017","journal-title":"Investig Clin Urol"},{"issue":"1","key":"zoi260606r10","doi-asserted-by":"publisher","first-page":"41.e23","DOI":"10.1016\/j.urolonc.2013.04.013","article-title":"Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.","volume":"32","author":"Cohn","year":"2014","journal-title":"Urol Oncol"},{"issue":"5","key":"zoi260606r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11869","article-title":"Association of the USPSTF Grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality.","volume":"5","author":"Burgess","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi260606r12","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300289","article-title":"Prostate Cancer Foundation screening guidelines for Black men in the United States.","author":"Garraway","journal-title":"NEJM Evid"},{"issue":"1","key":"zoi260606r13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/jnci\/djad193","article-title":"Prostate cancer screening in African American men: a review of the evidence.","volume":"116","author":"Kensler","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"zoi260606r14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality\u2014the future of PSA screening.","volume":"382","author":"Welch","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260606r15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","article-title":"NCCN Guidelines\u00ae insights: prostate cancer early detection, Version 1.2023.","volume":"21","author":"Moses","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi260606r16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO Guideline Part I: prostate cancer screening.","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"issue":"5","key":"zoi260606r17","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.eururo.2012.01.008","article-title":"The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.","volume":"61","author":"Wu","year":"2012","journal-title":"Eur Urol"},{"key":"zoi260606r18","doi-asserted-by":"publisher","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"issue":"18","key":"zoi260606r19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/jnci\/djm119","article-title":"Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.","volume":"99","author":"Welch","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"zoi260606r20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/archinternmed.2010.221","article-title":"Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng\/ml.","volume":"170","author":"Shao","year":"2010","journal-title":"Arch Intern Med"},{"issue":"15","key":"zoi260606r21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70007","article-title":"Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration.","volume":"131","author":"Green-Lott","year":"2025","journal-title":"Cancer"},{"issue":"9","key":"zoi260606r22","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/cncr.23695","article-title":"Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.","volume":"113","author":"Chamie","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"zoi260606r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44027","article-title":"Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system.","volume":"5","author":"Yamoah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi260606r24","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1001\/jamaoncol.2022.4319","article-title":"Association of prostate-specific antigen screening rates with subsequent metastatic prostate cancer incidence at US Veterans health administration facilities.","volume":"8","author":"Bryant","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"zoi260606r25","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1097\/01.ju.0000061183.43229.2e","article-title":"Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.","volume":"169","author":"Hugosson","year":"2003","journal-title":"J Urol"},{"issue":"2","key":"zoi260606r26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of follow-up in the G\u00f6teborg Randomized Population-Based Prostate Cancer Screening Trial.","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"zoi260606r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.2852","article-title":"Neighborhood deprivation, race and ethnicity, and prostate cancer outcomes across California health care systems.","volume":"7","author":"Wadhwa","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"26","key":"zoi260606r28","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making neighborhood-disadvantage metrics accessible\u2014The Neighborhood Atlas.","volume":"378","author":"Kind","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi260606r29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN Clinical Practice Guidelines in Oncology.","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"zoi260606r30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/sim.4780141510","article-title":"Graphical methods for assessing violations of the proportional hazards assumption in Cox regression.","volume":"14","author":"Hess","year":"1995","journal-title":"Stat Med"},{"issue":"7","key":"zoi260606r31","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data.","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"5","key":"zoi260606r32","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias.","volume":"15","author":"Hern\u00e1n","year":"2004","journal-title":"Epidemiology"},{"issue":"12","key":"zoi260606r33","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/sim.3585","article-title":"Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death.","volume":"28","author":"Cain","year":"2009","journal-title":"Stat Med"},{"issue":"6","key":"zoi260606r34","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models.","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"4","key":"zoi260606r35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/EDE.0000000000001032","article-title":"Bounding bias due to selection.","volume":"30","author":"Smith","year":"2019","journal-title":"Epidemiology"},{"issue":"4","key":"zoi260606r37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10552-020-01389-8","article-title":"Family history of prostate cancer and prostate tumor aggressiveness in black and non-black men; results from an equal access biopsy study.","volume":"32","author":"Jenkins","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"4","key":"zoi260606r38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/pros.2990170409","article-title":"Family history and the risk of prostate cancer.","volume":"17","author":"Steinberg","year":"1990","journal-title":"Prostate"},{"issue":"2","key":"zoi260606r39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2021.12.011","article-title":"Defining the impact of family history on detection of high-grade prostate cancer in a large multi-institutional cohort.","volume":"82","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"zoi260606r40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.urology.2012.10.074","article-title":"Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy?","volume":"81","author":"Elshafei","year":"2013","journal-title":"Urology"},{"issue":"4","key":"zoi260606r41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/0969141321989738","article-title":"Impact of cancer screening on metastasis: a prostate cancer case study.","volume":"28","author":"Lange","year":"2021","journal-title":"J Med Screen"},{"issue":"2","key":"zoi260606r42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59766","article-title":"Prostate cancer mortality in men aged 70 years who recently underwent prostate-specific antigen screening.","volume":"8","author":"Chung","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260606r43","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","article-title":"Risk-adjusted screening for prostate cancer\u2014defining the low-risk group by data from the PROBASE trial.","volume":"86","author":"Krilaviciute","year":"2024","journal-title":"Eur Urol"},{"issue":"11","key":"zoi260606r44","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial.","volume":"150","author":"Arsov","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"zoi260606r45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bju.16311","article-title":"Evolution of European prostate cancer screening protocols and summary of ongoing trials.","volume":"134","author":"van Harten","year":"2024","journal-title":"BJU Int"},{"issue":"5","key":"zoi260606r46","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/jnci\/djaa120","article-title":"The association of Veterans\u2019 PSA screening rates with changes in USPSTF recommendations.","volume":"113","author":"Becker","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"zoi260606r47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.euo.2025.06.007","article-title":"Do we need early detection of grade group 2 prostate cancer in a screening program for young men? Results from the PROBASE Screening Trial.","volume":"9","author":"Albers","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"zoi260606r48","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jnma.2018.10.010","article-title":"Prostate cancer screening guidelines for African American Veterans: a new perspective.","volume":"112","author":"Reddy","year":"2020","journal-title":"J Natl Med Assoc"},{"key":"zoi260606r49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2340\/1651-226X.2024.25053","article-title":"Agent Orange exposure and prostate cancer risk in the Million Veteran program.","volume":"63","author":"Pagadala","year":"2024","journal-title":"Acta Oncol"},{"issue":"5","key":"zoi260606r50","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/jnci\/djab058","article-title":"Evaluation of a multiethnic polygenic risk score model for prostate cancer.","volume":"114","author":"Plym","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi260606r51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eururo.2023.01.022","article-title":"Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry.","volume":"84","author":"Chen","year":"2023","journal-title":"Eur Urol"},{"issue":"14","key":"zoi260606r52","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer.","volume":"392","author":"McHugh","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260606r53","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/jnci\/djab062","article-title":"Association of health-care system with prostate cancer-specific mortality in African American and Non-Hispanic White men.","volume":"113","author":"Klebaner","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi260606r54","doi-asserted-by":"publisher","first-page":"34.e9","DOI":"10.1016\/j.urolonc.2013.01.003","article-title":"Do racial disparities exist in the use of prostate cancer screening and detection tools in Veterans?","volume":"32","author":"Hudson","year":"2014","journal-title":"Urol Oncol"},{"issue":"2","key":"zoi260606r55","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s43018-025-01103-0","article-title":"Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.","volume":"7","author":"Vassy","year":"2026","journal-title":"Nat Cancer"},{"key":"zoi260606r56","doi-asserted-by":"publisher","first-page":"g7773","DOI":"10.1136\/bmj.g7773","article-title":"Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods.","volume":"350","author":"Carter","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"zoi260606r57","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer.","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"12","key":"zoi260606r58","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI.","volume":"391","author":"Hugosson","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260606r59","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2024.04.037","article-title":"Performance of 4Kscore as a reflex test to prostate-specific antigen in the G\u00d6TEBORG-2 Prostate Cancer Screening Trial.","volume":"86","author":"Josefsson","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"zoi260606r60","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/1055-9965.EPI-23-1470","article-title":"Projecting the impact of multi-cancer early detection on late-stage incidence using multi-state disease modeling.","volume":"33","author":"Lange","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"62","key":"zoi260606r61","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/jncimonographs\/lgad018","article-title":"Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors.","volume":"2023","author":"Gulati","year":"2023","journal-title":"J Natl Cancer Inst Monogr"},{"key":"zoi260606r36","volume-title":"Urologic Cancers","author":"Raghallaigh","year":"2022"},{"key":"zoi260606r62","unstructured":"US Department of Veterans Affairs National Veteran health equity report\u2014Black or African American veteran chartbook: focus on Veterans Health Administration patient experience and health care quality. Published February 2023. Accessed October 10, 2025. https:\/\/purl.fdlp.gov\/GPO\/gpo238308"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851136\/siavoshi_2026_oi_260606_1782493109.92985.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:03:49Z","timestamp":1783350229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.21741","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}